Association between exposure to topical tacrolimus or pimecrolimus and cancers

Annals of Pharmacotherapy

Volumn 43, Issue 12, 2009, Pages 1956-1963

  Hui, Rita L ^a   Lide, William ^b   Chan, James ^a   Schottinger, Joanne ^a   Yoshinaga, Monica ^a   Millares, Mirta ^a  

^a KAISER PERMANENTE   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

Atopic dermatitis; Cancer; Eczema; Pimecrolimus; T cell lymphoma; Tacrolimus

Indexed keywords

ALEFACEPT; CALCIPOTRIOL; DITHRANOL; EFALIZUMAB; ETRETIN; ETRETINATE; METHOXSALEN; PIMECROLIMUS; PSORALEN; TACROLIMUS; TAZAROTENE; TRIOXYSALEN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; B CELL LYMPHOMA; BREAST CANCER; BRONCHUS CANCER; CANCER DIAGNOSIS; CANCER RISK; CHILD; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; ECZEMA; FEMALE; FEMALE GENITAL TRACT CANCER; HEALTH CARE DELIVERY; HUMAN; INFANT; KIDNEY CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; MEDICAL RECORD REVIEW; MELANOMA; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NEWBORN; OBSERVATIONAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PSORIASIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SEX; T CELL LYMPHOMA;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; CALCINEURIN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DERMATITIS, ATOPIC; ECZEMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; TACROLIMUS; YOUNG ADULT;

EID: 72249103790     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M278     Document Type: Article

References (22)

1. FDA issues public health advisory informing health care providers of safety concerns associated with the use of two eczema drugs, Elidel and Protopic. Rockville, MD: Center for Drug Evaluation and Research/Center for Biologics Evaluation and Research, Food and Drug Administration, March 2005. www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ ucm051760.htm (accessed 2009 Jul 2).
2. FDA pediatric advisory briefing information. Rockville, MD: Food and Drug Administration, February 2005. www.fda.gov/ohrms/dockets/ac/05/ briefing/2005- 4089b2.htm (accessed 2009 Jul 2).
3. Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 2005;153:701-705 DOI 10.1111/j.1365-2133.2005.06899.x
4. Package insert. Protopic (tacrolimus ointment). Deerfield, IL: Astellas Pharma US, Inc. www.astellas.us/docs/protopic-8c2e5036-5f1b-4e71- bf87-5faef295fa96.xml (accessed 2009 Jul 2).
5. Package insert. Elidel (pimecrolimus cream). East Hanover, NJ: Novartis Pharmaceuticals Corp. www.pharma.us.novartis.com/product/pi/pdf/elidel. pdf (accessed 2009 Jul 2).
6. Protopic dear healthcare provider letter. Deerfield, IL: Astellas Pharma, January 2006. www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/UCM153197.pdf (accessed 2009 Jul 2).
7. Elidel dear healthcare provider letter. East Hanover, NJ: Novartis Pharmaceuticals, January 2006. www.fda.gov/downloads/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM153194. pdf (accessed 2009 Jul 2).
8. Protopic medication guide. Rockville, MD: Food and Drug Administration, January 2006. www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm107848. pdf (accessed 2009 Jul 2).
9. Elidel medication guide. Rockville, MD: Food and Drug Administration, January 2006. www.fda.gov/downloads/Drugs/DrugSafety/UCM088587. pdf (accessed 2009 Jul 2).
10. Wooltorton E. Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns. CMAJ 2005;172:1179-1180 DOI 10.1503/cmaj.050373 (Pubitemid 40592671)
11. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007;214:289-295 DOI 10.1159/000100879 (Pubitemid 46659010)
12. Tamim H, Monfared AA, LeLorier J. Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf 2007;16:250-258 DOI 10.1002/pds.1360 (Pubitemid 46431688)
13. California cancer registry. www.ccrcal.org/abouttheccr.html (accessed 2009 Jul 2).
14. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008;167:492-499 DOI 10.1093/aje/kwm324
15. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 2005;352:1371-1373 DOI 10.1056/NEJMe058018 (Pubitemid 40411505)
16. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006; 126:2194-2201 DOI 10.1038/sj.jid.5700410
17. Vakeva L, Sarna S, Vaalasti A, Pukkala E, Kariniemi AL, Ranki A. A retrospective study of the probability of the evolution of parapsoriasis en plaques into mycosis fungoides. Acta Derm Venereol 2005;85:318-323 DOI 10.1080/00015550510030087 (Pubitemid 41113513)
18. Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007;127: 808-816 DOI 10.1038/sj.jid.5700622 (Pubitemid 46434650)
19. Kalthoff FS, Winiski A, Fichtinger P, et al. Differential inhibition of primary versus preactivated T cells by pimecrolimus but not by tacrolimus in vitro. Int Arch Allergy Immunol 2007;142:255-264 DOI 10.1159/000097028 (Pubitemid 46272374)
20. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46:495-504. DOI 10.1067/mjd.2002.122187
21. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997;337:816-821 DOI 10.1056/ NEJM199709183371203
22. Berger TG, Duvic M, Van Voorhees AS, VanBeek MJ, Frieden IJ. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006;54:818-823 DOI 10.1016/j.jaad.2006.01.054